Arcturus Therapeutics Holdings Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-05-08$9.22 RISE2026-05-19$6.69 PEAK2026-05-28$7.92 20d | -27.4% 11d | Missed | Missed | — | — | +18.4% 9d | Missed |
DROP2025-11-04$8.93 RISE2026-03-17$6.39 PEAK2026-05-08$9.22 185d | -28.4% 133d | Missed | Missed | — | — | +44.3% 52d | Missed |
DROP2025-10-21$23.16 RISE2025-12-31$6.13 PEAK2026-03-02$8.35 132d | -73.5% 71d | Missed | Missed | — | — | +36.2% 61d | Missed |
DROP2025-10-21$23.16 RISE2025-11-20$5.90 PEAK2026-02-19$7.97 121d | -74.5% 30d | Missed | Missed | — | — | +35.1% 91d | Missed |
DROP2025-07-23$15.45 RISE2025-08-11$11.39 PEAK2025-10-21$23.16 90d | -26.3% 19d | Missed | Missed | — | — | +103.3% 71d | Missed |
DROP2025-01-07$20.83 RISE2025-04-08$8.91 PEAK2025-06-26$14.41 170d | -57.2% 91d | Missed | Missed | — | — | +61.7% 79d | Missed |
DROP2024-10-02$25.48 RISE2024-12-18$14.82 PEAK2025-01-07$20.83 97d | -41.8% 77d | Missed | Missed | — | — | +40.6% 20d | Missed |
DROP2024-10-02$25.48 RISE2024-11-15$16.02 PEAK2025-01-07$20.83 97d | -37.1% 44d | Missed | Missed | — | — | +30.0% 53d | Missed |
DROP2024-06-05$44.39 RISE2024-08-09$18.08 PEAK2024-10-02$25.48 119d | -59.3% 65d | Missed | Missed | — | — | +40.9% 54d | Missed |
DROP2024-02-27$42.99 RISE2024-04-30$25.57 PEAK2024-06-05$44.39 99d | -40.5% 63d | Missed | Missed | — | — | +73.6% 36d | Missed |
DROP2023-07-18$37.35 RISE2023-11-13$17.71 PEAK2024-02-09$39.64 206d | -52.6% 118d | Missed | Missed | — | — | +123.8% 88d | Missed |
DROP2023-07-18$37.35 RISE2023-08-08$25.73 PEAK2023-08-23$32.67 36d | -31.1% 21d | Missed | Missed | — | — | +27.0% 15d | Missed |
DROP2023-05-11$32.36 RISE2023-06-23$23.94 PEAK2023-07-18$37.35 68d | -26.0% 43d | Missed | Missed | — | — | +56.0% 25d | Missed |
DROP2023-02-02$22.91 RISE2023-03-22$14.72 PEAK2023-05-11$32.36 98d | -35.7% 48d | Missed | Missed | — | — | +119.8% 50d | Missed |
DROP2022-11-04$23.38 RISE2022-12-28$16.24 PEAK2023-02-02$22.91 90d | -30.5% 54d | Missed | Missed | — | — | +41.1% 36d | Missed |
1–15 / 29 1 / 2 | |||||||
Moby summary of Arcturus Therapeutics Holdings Inc.'s Q1 2026 earnings call
Presentation Operator MessageOperator Hello, and welcome, everyone, joining today's Arcturus Therapeutics First Quarter 2026 Earnings Call. [Operator Instructions] Please note, this call is being...
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (NASDAQ:ARCT) executives highlighted progress in two rare-disease clinical programs and outlined a strengthened cash runway during the company’s first-quarter 2026 earnings call, while also discussing ongoing partner activity for its self-amplifying mRNA COVID-19 vaccine in Jap
Arcturus Q1 2026 revenue miss of $2.06M vs $7.38M estimates sent shares down 19.4%, despite pipeline progress in CF and OTC deficiency programs and a cash runway through Q2 2028.
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
-SEC Filing
SAN DIEGO — SAN DIEGO — Arcturus Therapeutics on Thursday reported a loss of $27 million in its first quarter. The San Diego-based company said it had a loss of 95 cents per share. The...
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.00) by 5 percent. This is a 82.69 percent decrease over losses of $(0.52) per share from
Initiated enrollment earlier than expected for 12‑week cystic fibrosis open label Phase 2 study; lung function is being monitored in Class I CF subjectsReceived regulatory direction on...
Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics Holdings Inc. , a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its...
The widely followed investor has been buying stocks trading well below their all-time highs.
Arcturus Therapeutics (NASDAQ:ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payne said Arcturus had initiated a rare disease strategy for messen
The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting.
Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.
Wall Street analysts upgraded top stocks, including Chipotle, ARM, BP, and Solaredge. See what they think about buying BP stock.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ARCT | -8.23% | -5.15% | +29.20% | -36.79% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.20% | +0.57% | +32.64% | -49.48% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| ARKK | disruptive | 2.77M | $21.38M | 0.17% | Added+6.1% | 2026-03-31 |
| TwoSigma | quant | 1.08M | $8.35M | 0.01% | Added+97.9% | 2026-03-31 |
| StateStreet | passive | 543.9K | $4.20M | 0.00% | Trimmed-3.6% | 2026-03-31 |
| DEShaw | quant | 252.0K | $1.95M | 0.00% | Added+157.6% | 2026-03-31 |
| RenTech | quant | 178.3K | $1.38M | 0.00% | Added+48.7% | 2026-03-31 |
| Citadel | multi-strat | 63.8K | $492.88K | 0.00% | Trimmed-71.3% | 2026-03-31 |
| FidelityFMR | fundamental | 4.6K | $35.67K | 0.00% | Added+42.8% | 2026-03-31 |
| TRowePrice | fundamental | 29.8K | $231 | 0.00% | Added+14.1% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -1.03 | — | — |
| 2026-05-06 | -1.01 | -0.95 | +6.25% |
| 2026-03-03 | -0.76 | -1.03 | -36.40% |
| 2025-11-10 | -0.80 | -0.49 | +38.71% |
| 2025-08-11 | -0.85 | -0.34 | +59.81% |
| 2025-05-12 | -1.10 | -0.52 | +52.67% |
| 2025-03-06 | -0.49 | -1.11 | -124.56% |
| 2024-11-07 | -1.02 | -0.26 | +74.60% |
| 2024-08-05 | -1.57 | -0.64 | +59.23% |
| 2024-05-08 | -1.14 | -1.00 | +12.59% |
| 2024-03-07 | -1.05 | -0.32 | +69.62% |
| 2023-11-14 | -1.63 | -0.61 | +62.47% |
| 2023-08-07 | -0.42 | -1.98 | -372.32% |
| 2023-05-09 | 0.26 | 0.63 | +142.12% |
| 2023-03-28 | 1.23 | 4.33 | +253.05% |
| 2022-11-09 | -1.81 | -1.33 | +26.69% |